U.S. patent application number 17/538197 was filed with the patent office on 2022-03-24 for novel morphinans useful for treating medical disorders.
The applicant listed for this patent is Humanwell Pharmaceutical US. Invention is credited to Wentao Du, Jie Li, Lie Li, Subo Liao, Zongquan Liao, Jinliang Lv, Tianpeng Xie, Jun Yang, Jianbo Yu, Hao Zhou.
Application Number | 20220089605 17/538197 |
Document ID | / |
Family ID | 1000006000498 |
Filed Date | 2022-03-24 |
United States Patent
Application |
20220089605 |
Kind Code |
A1 |
Liao; Subo ; et al. |
March 24, 2022 |
NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS
Abstract
The present invention related to novel morphinans, compositions
comprising the novel morphinans, and their uses as agonists of the
kappa opioid receptor.
Inventors: |
Liao; Subo; (Ballwin,
MO) ; Yang; Jun; (Ballwin, MO) ; Li; Jie;
(Ballwin, MO) ; Du; Wentao; (Ballwin, MO) ;
Li; Lie; (Ballwin, MO) ; Lv; Jinliang;
(Ballwin, MO) ; Liao; Zongquan; (Ballwin, MO)
; Zhou; Hao; (Ballwin, MO) ; Xie; Tianpeng;
(Ballwin, MO) ; Yu; Jianbo; (Ballwin, MO) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Humanwell Pharmaceutical US |
Ballwin |
MO |
US |
|
|
Family ID: |
1000006000498 |
Appl. No.: |
17/538197 |
Filed: |
November 30, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16834449 |
Mar 30, 2020 |
11214577 |
|
|
17538197 |
|
|
|
|
62826188 |
Mar 29, 2019 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 491/08
20130101 |
International
Class: |
C07D 491/08 20060101
C07D491/08 |
Claims
1. A compound of Formula (I) or a pharmaceutically acceptable salt
thereof: ##STR00018## wherein: R is hydrogen, methyl, allyl,
cyclopropylmethyl, 1-hydroxylcyclopropylmethyl, or
cyclobutylmethyl; R.sup.1 and R.sup.2 independently are hydrogen,
halogen, hydroxy, alkoxy, or aryloxy; R.sup.3 is hydrogen, hydroxy,
alkoxy, or alkanoate; R.sup.7 and R.sup.8 independently are
hydrogen, alkyl, or substituted alkyl; R.sup.10 is hydrogen,
hydroxy, alkyoxy, or keto; R.sup.14 is hydrogen, hydroxy, or
alkoxy; one of R.sup.20, R.sup.21, R.sup.22, and R.sup.23 is
represented by the compound of Formula (II) and the rest are chosen
from hydrogen or halogen, and R.sup.24 is hydrogen; ##STR00019##
R.sup.25 is hydrogen, alkyl, substituted aryl, alkylaryl,
substituted alkylaryl, heterocycle, or substituted heterocycle;
R.sup.26 and R.sup.27 independently are H, Cl, Br, F, CF.sub.3, CN,
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl,
substituted aryl, or heterocycle; R.sup.28 is hydrogen or halogen;
R.sup.29 is absent, hydrogen, or C.sub.1-C.sub.6 alkyl; X is
nitrogen; Y is selected from a group consisting of O, S, and N; and
the dashed line represents an optional double bond; wherein the
substitution on R.sup.26 and R.sup.27 independently are Cl, Br, F,
CF.sub.3, CN, C.sub.1-C.sub.6 alkyl, or C.sub.3-C.sub.6
cycloalkyl.
2. The compound of claim 1, wherein the carbons attached to
R.sup.20-R.sup.24 on the cyclopropyl ring independently have an R
or S configuration.
3. The compound of claim 1, wherein heterocycle is chosen from a
group consisting of furyl, benzofuryl, oxazolyl, isoxazolyl,
oxadiazolyl, benzoxazolyl, benzoxadiazolyl, pyrrolyl, pyrazolyl,
imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl,
pyridazinyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl,
indazolyl, benzotriazolyl, tetrazolopyridazinyl, carbazolyl,
purinyl, quinolinyl, isoquinolinyl, thienyl, phenol, and
imidazopyridyl.
4. The compound of claim 1, wherein; R.sup.3 is hydroxy,
C.sub.1-C.sub.4 alkyoxy, or alkanoate; R.sup.7 and R.sup.8 are each
hydrogen, R.sup.14 is hydrogen or hydroxy; R.sup.20, R.sup.21,
R.sup.23, and R.sup.24 are hydrogen, R.sup.22 is furyl, substituted
furyl, thienyl, substituted thienyl, pyrrole or substituted
pyrrole; and R.sup.25 is C.sub.1-C.sub.4 alkyl.
5. The compound of claim 1, wherein R is cyclopropylmethyl; R.sup.3
is hydroxy; R.sup.14 is hydroxy; and R.sup.25 is methyl; R.sup.26
is hydrogen; R.sup.27 is Cl; and Y is O.
6. The compound of claim 1, wherein R is cyclopropylmethyl; R.sup.3
is hydroxy; R.sup.14 is hydroxy; and R.sup.25 is methyl; R.sup.26
and R.sup.27 are Cl; and Y is O.
7. The compound of claim 1, wherein R is cyclopropylmethyl; R.sup.3
is hydroxy; R.sup.14 is hydroxy; and R.sup.25 is methyl; R.sup.26
is hydrogen; R.sup.27 is CF.sub.3; and Y is O.
8. The compound of claim 1, which has an optical activity of (-) or
(+); and carbons C-5, C-13, C-14, and C-9, respectively, have a
configuration chosen from RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS,
RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, or SSSS, provided
that the C-15 and the C-16 carbons are both either on the alpha
face of the molecule or the beta face of the molecule.
9. The compound of claim 1, wherein carbon C-6 has an alpha
configuration or a beta configuration.
10. A pharmaceutical composition comprising a compound of claim 1
and at least one pharmaceutically acceptable excipient.
11. A method for treating a kappa opioid receptor-related disease
or disorder, the method comprising administering a pharmaceutically
effective amount of the pharmaceutical composition of claim 10 to
an individual in need thereof; wherein the wherein the kappa opioid
receptor-related disease or disorder is pain, pruritis, or an
addiction.
12. The method of claim 10, wherein addiction is substance abuse
addiction.
13. The method of claim 10, wherein pain is chronic pain, visceral
pain, neuropathic pain, and post-surgical pain.
14. The method of claim 10, wherein the individual is a human.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation of U.S. application Ser.
No. 16/834,449, filed Mar. 30, 2020 which claims the benefit of
U.S. Provisional Application No. 62/826,188, filed Mar. 29, 2019,
all of which is incorporated herein by reference in its entirety
for all purposes.
FIELD OF THE INVENTION
[0002] The present disclosure generally relates to novel morphinans
useful in treating medical disorders.
BACKGROUND OF THE INVENTION
[0003] Kappa opioid receptors (KORs) exist in many parts of the
body such as brain, spinal cord, and on central and peripheral
terminals. KORs play an important role in signal transduction; like
other two opioid receptors mu opioid receptors (MORs) and delta
opioid receptors (DORs). Agonist-induced activation of KORs leads
to the inhibition of adenylyl cyclase and calcium channel activity
while stimulation of the potassium channel activities (see Law P Y,
Wong Y H, Loh H H; "Molecular mechanisms and regulation of opioid
receptor signaling" Annu Rev Pharmacol Toxicol 2000; 40:
389-430).
[0004] A variety of physiological processes are related to the
activation of KORs such as analgesia, anti-pruritic actives (see
Irian S, Cowan A. "Kappa opioid agonists suppress
chloroquine-induced scratching in mice." Eur J. Pharmacol 2004;
502, 233-7) and diuresis (see Barber A, Gottschlich R. "Novel
developments with selective non-peptidic kappa-opioid receptor
agonists." Exp Opinion Investigational drugs. 1997; 6: 1351-68;
DeHaven-Hudkins D L, Dolls R. E.; "Peripherally restricted opioid
agonists as novel analgesic agents." Curr Pharm Des 2004;
10:743-57), inflammation, immune system modulation, et al. which
offer great potentials for KORs to treat many medical disorder such
as pain, depression, autoimmune disorders, and neurological
diseases.
[0005] Many KORs selective agonists were designed as potential
analgesics in an attempt to avoid of side effects associated with
traditional opioid analgesics such as respiratory depression,
dependence, addiction, and constipation. Some KORs have been tested
in clinical trial but failed due to side effects like diuresis,
sedation, and dysphoria, et al or lack of efficacy. Some examples
include spiradoline mesylate (see Wadenberg M L, "A review of the
properties of spiradoline: a potent and selective kappa-opioid
receptor agonist." CNS Drug Rev. 2003, Summer, 9(2): 187-98),
enadoline for potential analgesics (see Walsh S L., Strain E C,
Abreu M. E. Bigelow G. E.; "Enadoline, a selective kappa opioid
agonist: comparison with butorphanol and hydromorphone in humans."
Psychopharmacology 2001, 157, 151-162), and ADL-10-0101.
[0006] CR-845 is another KORs agonist currently in the clinical
trials for analgesics and anti-pruritic agents. TRK-820 was
originally developed as potential analgesics but achieved success
as anti-pruritic reagents and received regulatory approval in
Japan.
[0007] KORs agonists are also developed for other indications such
fedotozine as potential therapeutics for irritable bowel syndrome
and dyspepsia, and asimadoline as potential treatment for irritable
bowel syndrome and functional dyspepsia.
[0008] What is needed is a novel opioid kappa agonists which has
potential therapeutic value to treat various KORs-related medical
disorder without side effects.
BRIEF DESCRIPTION OF FIGURES
[0009] FIG. 1 is a response curve of compound 5a measuring the %
effect versus the log of the concentration (nM) which affords the
EC.sub.50.
SUMMARY OF THE INVENTION
[0010] Among the various aspects of the present disclosure is
compound comprising Formula (I):
##STR00001##
[0011] wherein:
[0012] R is hydrogen, alkyl, substituted alkyl, cycloalkyl, alkyl
cycloalkyl, alkenyl, substituted alkenyl, aryl, substitute aryl,
alkylaryl, or substituted alkylaryl;
[0013] R.sup.1 and R.sup.2 independently are hydrogen, halogen,
hydroxy, alkoxy, aryloxy, amino, amine, nitro, alkyl, or
substituted alkyl;
[0014] R.sup.3 is hydrogen, hydroxy, alkyoxy, aryloxy, halogen,
amino, or thiol; R.sup.7 and R.sup.8 independently are hydrogen,
halogen, hydroxy, alkoxy, amino, amine, thiol, alkyl, or
substituted alkyl;
[0015] R.sup.10 is hydrogen, hydroxy, alkyoxy, keto, ether, ester,
amino, or amine;
[0016] R.sup.14 is hydrogen, hydroxy, or alkoxy;
[0017] R.sup.20, R.sup.21, R.sup.22, R.sup.23, and R.sup.24
independently are hydrogen, halogen, alkyl, substituted alkyl,
alkenyl, substituted alkynyl, aryl, substituted aryl, alkylaryl,
substituted alkylaryl, heterocycle, substituted heterocycle,
alkylheterocycle, or substituted alkylheterocycle;
[0018] R.sup.25 is hydrogen, halogen, alkyl, substituted alkyl,
alkenyl, substituted alkynyl, aryl, substituted aryl, alkylaryl,
substituted alkylaryl, heterocycle, substituted heterocycle,
alkylheterocycle, substituted alkylheterocycle, or absent;
[0019] X is nitrogen, oxygen, or sulfur; and
[0020] the dashed line represents an optional double bond.
[0021] In another aspect, the present disclosure provides
pharmaceutical compositions comprising any of the compounds of
Formula (I) and at least one pharmaceutically acceptable
excipient.
[0022] In still another aspect, the present disclosure provides a
method for treating a kappa opioid receptor-related disease or
disorder. The method comprises administrating the composition
comprising a compound of Formula (I) to an individual in need
thereof.
[0023] Other features and iterations of the invention are described
in more detail below.
DETAILED DESCRIPTION OF THE INVENTION
[0024] The present disclosure provides compounds comprising Formula
(I), pharmaceutical compositions comprising any of the compounds of
Formula (I) and at least one pharmaceutically acceptable excipient,
and methods for treating a kappa opioid receptor-related disease or
disorder. The compounds disclosed herein have been shown to be
selective to the kappa opioid receptor and, as such, would provide
a therapy for treating kappa opioid receptor-related diseases or
disorders.
[0025] (I) Compounds Comprising Formula (I)
[0026] One aspect of the present disclosure provides compounds
comprising Formula (I):
##STR00002##
[0027] wherein:
[0028] R is hydrogen, alkyl, substituted alkyl, cycloalkyl, alkyl
cycloalkyl, alkenyl, substituted alkenyl, aryl, substitute aryl,
alkylaryl, or substituted alkylaryl;
[0029] R.sup.1 and R.sup.2 independently are hydrogen, halogen,
hydroxy, alkoxy, aryloxy, amino, amine, nitro, alkyl, or
substituted alkyl;
[0030] R.sup.3 is hydrogen, hydroxy, alkyoxy, aryloxy, halogen,
amino, or thiol;
[0031] R.sup.7 and R.sup.8 independently are hydrogen, halogen,
hydroxy, alkoxy, amino, amine, thiol, alkyl, or substituted
alkyl;
[0032] R.sup.10 is hydrogen, hydroxy, alkyoxy, keto, ether, ester,
amino, or amine;
[0033] R.sup.14 is hydrogen, hydroxy, or alkoxy;
[0034] R.sup.20, R.sup.21, R.sup.22, R.sup.23, and R.sup.24
independently are hydrogen, halogen, alkyl, substituted alkyl,
alkenyl, substituted alkynyl, aryl, substituted aryl, alkylaryl,
substituted alkylaryl, heterocycle, substituted heterocycle,
alkylheterocycle, or substituted alkylheterocycle;
[0035] R.sup.25 is hydrogen, halogen, alkyl, substituted alkyl,
alkenyl, substituted alkynyl, aryl, substituted aryl, alkylaryl,
substituted alkylaryl, heterocycle, substituted heterocycle,
alkylheterocycle, substituted alkylheterocycle, or absent;
[0036] X is nitrogen, oxygen, or sulfur; and
[0037] the dashed line represents an optional double bond.
[0038] In some embodiments, R may be hydrogen, alkyl, substituted
alkyl, alkylcycloalkyl, alkenyl, substituted alkenyl, aryl,
substitute aryl, alkylaryl, or substituted alkylaryl. In other
embodiments, R may be hydrogen, methyl, allyl, cyclopropylmethyl,
or cyclobutylmethyl. In specific embodiments, R may be
cyclopropylmethyl or 1-hydroxylcycloproylmethyl.
[0039] In some embodiments, R.sup.1 and R.sup.2 independently may
be hydrogen, halogen, hydroxy, alkoxy, aryloxy, amino, amine,
nitro, alkyl, or substituted alkyl. In other embodiments, R.sup.1
and R.sup.2 independently may be hydrogen, hydroxyl, methoxy,
methyl, or chloride. In specific embodiments, R.sup.1 and R.sup.2
may be hydrogen.
[0040] In some embodiments, R.sup.3 may be hydrogen, hydroxy,
alkyoxy, aryloxy, halogen, amino, or thiol. In other embodiments,
R.sup.3 may be hydroxy, methoxy, ethoxy, isopropoxy, or phenoxy. In
specific embodiments, R.sup.3 may be hydroxyl.
[0041] In some embodiments, R.sup.7 and R.sup.8 independently may
be hydrogen, halogen, hydroxy, alkoxy, amino, amine, thiol, alkyl,
or substituted alkyl. In other embodiments, R.sup.7 and R.sup.8
independently may be hydrogen, chloro, hydroxyl, amino, methoxy, or
methyl. In specific embodiments, R.sup.7 and R.sup.8 may be
hydrogen.
[0042] In some embodiments, R.sup.10 may be hydrogen, hydroxy,
alkyoxy, keto, ether, ester, amino, or amine. In other embodiments,
R.sup.10 may be hydrogen, hydroxy, methoxy, or amine. In specific
embodiments, R.sup.10 may be hydrogen.
[0043] In some embodiments, R.sup.14 may be hydrogen, hydroxy, or
alkoxy. In other embodiments, R.sup.14 may be hydrogen or hydroxy.
In specific embodiments, R.sup.14 may be hydrogen.
[0044] In some embodiments, R.sup.20, R.sup.21, R.sup.22, R.sup.23,
and R.sup.24 independently may be hydrogen, halogen, alkyl,
substituted alkyl, alkenyl, substituted alkynyl, aryl, substituted
aryl, alkylaryl, substituted alkylaryl, heterocycle, substituted
heterocycle, alkylheterocycle, or substituted alkylheterocycle
wherein heterocycle is chosen from furyl, benzofuryl, oxazolyl,
isoxazolyl, oxadiazolyl, benzoxazolyl, benzoxadiazolyl, pyrrolyl,
pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl,
pyrazinyl, pyridazinyl, indolyl, isoindolyl, indolizinyl,
benzimidazolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl,
carbazolyl, purinyl, quinolinyl, isoquinolinyl, thienyl, phenol, or
imidazopyridyl. In other embodiments, at least one of R.sup.20,
R.sup.21, R.sup.22, R.sup.23, and R.sup.24 may be aryl, substituted
aryl, alkylaryl, substituted alkylaryl, heterocycle, substituted
heterocycle, alkylheterocycle, or substituted alkylheterocycle
wherein the heterocycle is defined above. In another embodiment,
one of R.sup.20, R.sup.21, R.sup.22, and R.sup.23 is a heterocycle
or substituted heterocycle and the rest are chosen from hydrogen or
halogen, and R.sup.24 may be hydrogen wherein heterocycle is
defined above. In specific embodiments, R.sup.20, R.sup.21,
R.sup.23, and R.sup.24 may be hydrogen and R.sup.22 may be furyl,
thienyl, or 4-hydroxyphenol.
[0045] In another embodiment, R.sup.25 may be hydrogen, halogen,
alkyl, substituted alkyl, alkenyl, substituted alkynyl, aryl,
substituted aryl, alkylaryl, substituted alkylaryl, heterocycle,
substituted heterocycle, alkylheterocycle, substituted
alkylheterocycle, or absent wherein the heterocycle is defined
above. In some embodiments, R.sup.25 may be hydrogen, alkyl, or
substituted alkyl. In an alternate embodiment, R.sup.25 may be
C.sub.1-C.sub.4 alkyl or substituted C.sub.1-C.sub.4 alkyl. In
specific embodiments, R.sup.25 may be methyl.
[0046] In one embodiment, X may be nitrogen, oxygen, or sulfur. In
other embodiment, X may be nitrogen or oxygen. In specific
embodiments, X may be nitrogen.
[0047] In other embodiments, the dashed line may represent an
optional double bond. In specific embodiments, the dashed line may
represent a single bond.
[0048] In exemplary embodiments, R may be cyclopropylmethyl or
1-hydroxylcyclopropylmethyl; R.sup.3 may be hydroxyl; R.sup.1,
R.sup.2, R.sup.7, R.sup.8, R.sup.10, R.sup.14, R.sup.20, R.sup.21,
R.sup.23, and R.sup.24 may be hydrogen; R.sup.22 may be furyl,
thienyl, or 4-hydroxyphenyl; and R.sup.25 may be methyl as shown
below.
##STR00003##
[0049] In general, the morphinans and normorphinans detailed herein
include any compound comprising a morphinan structure as diagrammed
below, wherein R is alkyl, substituted alkyl, alkylcycloalkyl,
alkenyl, substituted alkenyl, aryl, substitute aryl, alkylaryl, or
substituted alkylaryl in morphinans, and R is hydrogen in
normorphinans. For the purposes of illustration, the ring atoms of
the core morphinan structure are numbered as shown below:
##STR00004##
[0050] Morphinan compounds have asymmetric centers. In particular,
the core morphinan compound may have at least four chiral carbons
(designated by asterisks in the diagram above); namely, C-5, C-13,
C-14, and C-9.
[0051] The compound comprising Formula (I) may have a (-) or a (+)
orientation with respect to the rotation of polarized light. More
specifically, each chiral center of the morphinans or normorphinans
may have an R or an S configuration. The compounds described herein
may have at least four chiral centers, namely carbons C-5, C-9,
C-13, and C-14. At each chiral center, the stereochemistry at the
carbon atom is independently R or S. The configuration of C-5, C-9,
C-13, and C-14, respectively, may be RRRR, RRRS, RRSR, RSRR, SRRR,
RRSS, RSSR, SSRR, SRRS, SRSR, RSRS, RSSS, SRSS, SSRS, SSSR, or
SSSS, provided that the C-15 and C-16 atoms are both on the alpha
face of the molecule or both on the beta face of the molecule.
[0052] The group on C-6 of the compounds comprising Formula (I)
exist as alpha isomers or beta isomers. The alpha isomer to beta
isomer ratio of any of these compounds may be from about 0:100 to
about 100:0.
[0053] The carbons on the cyclopropyl ring of the compounds
comprising Formula (I) exist in either an R or S configuration.
[0054] The compound comprising Formula (I) may be a free form or a
salt. When the compound is in a salt form, the salt is preferably a
pharmaceutically acceptable salt. Pharmaceutically acceptable salts
may include, without limitation, hydrochloride, hydrobromide,
phosphate, sulfate, methanesulfonate, acetate, formate, tartaric
acid, bitartrate, stearate, phthalate, hydroiodide, lactate,
monohydrate, mucate, nitrate, phosphate, salicylate,
phenylpropionate, isobutyrate, hypophosphite, maleic, malic,
citrate, isocitrate, succinate, lactate, gluconate, glucuronate,
pyruvate, oxalate, fumarate, propionate, aspartate, glutamate,
benzoate, terephthalate, and the like. In other embodiments, the
pharmaceutically acceptable salt includes an alkaline or alkaline
earth metal ion salt. In particular, sodium, potassium or other
pharmaceutically acceptable inorganic salts are used. The salt
forms may be amorphous or in various polymeric forms including
hydrates, or solvates with alcohols or other solvents.
[0055] (II) Pharmaceutical Compositions
[0056] The disclosure also provides a pharmaceutical composition
comprising a compound comprising Formula (I) and at least one
pharmaceutically acceptable excipient.
[0057] (a) Compounds Comprising Formula (I)
[0058] The compounds comprising Formula (I) are described in more
detail in Section (I).
[0059] (b) Excipient
[0060] A pharmaceutical composition of the disclosure comprises at
least one pharmaceutically acceptable excipient. Non-limiting
examples of suitable excipients may include diluents, binders,
fillers, buffering agents, pH modifying agents, disintegrants,
dispersing agents, stabilizers, preservatives, and coloring agents.
The amount and types of excipients may be selected according to
known principles of pharmaceutical science.
[0061] In one embodiment, the excipient may include at least one
diluent. Non-limiting examples of suitable diluents may include
microcrystalline cellulose (MCC), cellulose derivatives, cellulose
powder, cellulose esters (i.e., acetate and butyrate mixed esters),
ethyl cellulose, methyl cellulose, hydroxypropyl cellulose,
hydroxypropyl methylcellulose, sodium carboxymethylcellulose, corn
starch, phosphated corn starch, pregelatinized corn starch, rice
starch, potato starch, tapioca starch, starch-lactose,
starch-calcium carbonate, sodium starch glycolate, glucose,
fructose, lactose, lactose monohydrate, sucrose, xylose, lactitol,
mannitol, malitol, sorbitol, xylitol, maltodextrin, and
trehalose.
[0062] In another embodiment, the excipient may comprise a binder.
Suitable binders may include, but are not limited to, starches,
pregelatinized starches, gelatin, polyvinylpyrrolidone, cellulose,
methylcellulose, sodium carboxymethylcellulose, ethylcellulose,
polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18
fatty acid alcohol, polyethylene glycol, polyols, saccharides,
oligosaccharides, polypeptides, oligopeptides, and combinations
thereof.
[0063] In another embodiment, the excipient may include a filler.
Suitable fillers may include, but are not limited to,
carbohydrates, inorganic compounds, and polyvinylpyrrolidone. By
way of non-limiting example, the filler may be calcium sulfate,
both di- and tri-basic, starch, calcium carbonate, magnesium
carbonate, microcrystalline cellulose, dibasic calcium phosphate,
magnesium carbonate, magnesium oxide, calcium silicate, talc,
modified starches, lactose, sucrose, mannitol, or sorbitol.
[0064] In still another embodiment, the excipient may comprise a
buffering agent. Buffers may include phosphates, carbonates,
citrates, and the like. Representative examples of suitable
buffering agents may include, but are not limited to, MOPS, HEPES,
TAPS, Bicine, Tricine, TES, PIPES, MES, Tris buffers or buffered
saline salts (e.g., Tris buffered saline or phosphate buffered
saline).
[0065] In various embodiments, the excipient may include a pH
modifier. By way of non-limiting example, the pH modifying agent
may be sodium carbonate or sodium bicarbonate.
[0066] In another alternate embodiment, the excipient may also
include a preservative. Non-limiting examples of suitable
preservatives may include antioxidants, such as alpha-tocopherol or
ascorbate, or EDTA (ethylenediaminetetraacetic acid), EGTA
(ethylene glycol tetraacetic acid), BHA (butylated hydroxyanisole),
BHT (butylated hydroxytoluene), and the like.
[0067] In a further embodiment, the excipient may include a
disintegrant. Suitable disintegrants may include, but are not
limited to, starches such as corn starch, potato starch,
pregelatinized and modified starches thereof, sweeteners, clays,
such as bentonite, micro-crystalline cellulose, alginates, sodium
starch glycolate, gums such as agar, guar, locust bean, karaya,
pecitin, and tragacanth.
[0068] In yet another embodiment, the excipient may include a
dispersion enhancer. Suitable dispersants may include, but are not
limited to, starch, alginic acid, polyvinylpyrrolidones, guar gum,
kaolin, bentonite, purified wood cellulose, sodium starch
glycolate, isoamorphous silicate, and microcrystalline
cellulose.
[0069] In a further embodiment, the excipient may include a
lubricant. Non-limiting examples of suitable lubricants may include
minerals such as talc or silica; and fats such as vegetable
stearin, magnesium stearate, or stearic acid.
[0070] In still another embodiment, it may be desirable to provide
a coloring agent. Suitable color additives may include, but are not
limited to, food, drug and cosmetic colors (FD&C), drug and
cosmetic colors (D&C), or external drug and cosmetic colors
(Ext. D&C).
[0071] The weight fraction of the excipient(s) in the composition
may be about 99% or less, about 95% or less, about 90% or less,
about 85% or less, about 80% or less, about 75% or less, about 70%
or less, about 65% or less, about 60% or less, about 55% or less,
about 50% or less, about 45% or less, about 40% or less, about 35%
or less, about 30% or less, about 25% or less, about 20% or less,
about 15% or less, about 10% or less, about 5% or less, about 2%,
or about 1% or less of the total weight of the composition.
[0072] The pharmaceutical composition may be mixed with one or more
excipients to form a solid, liquid, or cream dosage form. Methods
of formulating a solid, liquid, or cream dosage form are known in
the art.
[0073] (III) Processes to Prepare Compounds Comprising Formula
(I)
[0074] In yet another aspect, the present disclosure provides
processes to prepare compounds comprising Formula (I). The
processes commences by converting the 6-keto position on the
morphinan or nor-morphinan to the corresponding amino, hydroxyl, or
thiol group in either the alpha isomer or beta isomer. These
processes are disclosed and known in the arts.
[0075] The next step in the process comprises contacting the amino,
hydroxyl, or thiol group with an acyl group to form an amide, an
ester, or a thioester. These processes may utilize an acyl coupling
agent, a proton acceptor, and at least one solvent. These processes
may be conducted at various temperatures and pressures. Numerous
processes are known by the skilled artisan and disclosed in the
arts.
[0076] (IV) Methods of Treating Kappa Opioid Receptor-Related
Disease or Disorder
[0077] In still another aspect, the present disclosure provides a
method of treating a kappa opioid receptor-related disease or
disorder, wherein the method comprises administering to a subject
in need thereof a pharmaceutical composition comprising a compound
of Formula (I).
[0078] Without being bound to any theory, compounds comprising
Formula (I) are thought to mediate the kappa opioid receptor
activity primarily as an agonist. The binding at this site is
thought to treat pain, pruritis, addiction, depression, stress,
anxiety, autoimmune disorders, mycocardial infarction,
inflammation, edemia, emetic, or neurological diseases.
[0079] The compounds may be administered to the subject by a
variety of routes. For example, a compound comprising Formula (I)
may be administered orally via a solid or liquid dosage form
(tablet, gel cap, time release capsule powder, solution, or
suspension in aqueous or non-aqueous liquid), parenterally (i.e.,
subcutaneously, intradermally, intravenously, (i.e., as a solution,
suspension or emulsion in a carrier), intramuscularly,
intracranially, or intraperitoneally), or topically (i.e.,
transdermally or transmucosally, including, but not limited to
buccal, rectal, vaginal and sublingual). In one embodiment, the
compounds may be administered in saline or with a pharmaceutically
acceptable excipient as described above. The compound may be
administered as primary therapy, or as adjunct therapy, either
following local intervention (surgery, radiation, local
chemotherapy) or in conjunction with at least one other
chemotherapeutic agent.
[0080] Suitable subjects may include, without limit, humans, as
well as companion animals such as cats, dogs, rodents, and horses;
research animals such as rabbits, sheep, pigs, dogs, primates,
mice, rats and other rodents; agricultural animals such as cows,
cattle, pigs, goats, sheep, horses, deer, chickens and other fowl;
zoo animals; and primates such as chimpanzees, monkeys, and
gorillas. The subject can be of any age without limitation. In a
preferred embodiment, the subject may be a human.
[0081] Generally, the compound comprising Formula (I) will be
administered in a therapeutically effective amount which includes
prophylactic amounts or lower dosages for example, when combined
with another agent. As used herein, "an effective amount" refers to
doses of compound sufficient to provide circulating concentrations
high enough to impart a beneficial effect on the recipient thereof.
The precise amount to be administered can be determined by the
skilled practitioner in view of desired dosages, side effects, and
medical history of the patient.
[0082] Generally, the compounds comprising Formula (I) have an
EC.sub.50 of less than about 10 nM of the binding affinity of the
kappa receptor. In various embodiments, the compounds comprising
Formula (I) have an EC.sub.50 of less than about 10 nM, or less
than 8 nM, or less than about 4 nM, or less than about 1 nM. I
[0083] In general, the compounds of Formula (I) have an EC.sub.50
in the Flipr Calcium assay of less than 10 nM in whole cells. In
various embodiments, the compounds comprising Formula (I) have an
EC.sub.50 of less than about 10 nM, or less than 8 nM, or less than
about 4 nM, or less than about 3 nM.
Definitions
[0084] The compounds described herein have asymmetric centers.
Compounds of the present invention containing an asymmetrically
substituted atom may be isolated in optically active or racemic
form. All chiral, diastereomeric, racemic forms and all geometric
isomeric forms of a structure are intended, unless the specific
stereochemistry or isomeric form is specifically indicated.
[0085] The term "acyl," as used herein alone or as part of another
group, denotes the moiety formed by removal of the hydroxy group
from the group COOH of an organic carboxylic acid, e.g., RC(O)--,
wherein R is R.sup.1, R.sup.1O--, R.sup.1R.sup.2N--, or R.sup.1S--,
R.sup.1 is hydrocarbyl, heterosubstituted hydrocarbyl, or
heterocyclo, and R.sup.2 is hydrogen, hydrocarbyl, or substituted
hydrocarbyl.
[0086] The term "acyloxy," as used herein alone or as part of
another group, denotes an acyl group as described above bonded
through an oxygen linkage (O), e.g., RC(O)O-- wherein R is as
defined in connection with the term "acyl."
[0087] The term "alkyl" as used herein describes groups which are
preferably lower alkyl containing from one to eight carbon atoms in
the principal chain and up to 20 carbon atoms. They may be straight
or branched chain or cyclic and include methyl, ethyl, propyl,
isopropyl, butyl, hexyl and the like.
[0088] The term "alkenyl" as used herein describes groups which are
preferably lower alkenyl containing from two to eight carbon atoms
in the principal chain and up to 20 carbon atoms. They may be
straight or branched chain or cyclic and include ethenyl, propenyl,
isopropenyl, butenyl, isobutenyl, hexenyl, and the like.
[0089] The term "alkynyl" as used herein describes groups which are
preferably lower alkynyl containing from two to eight carbon atoms
in the principal chain and up to 20 carbon atoms. They may be
straight or branched chain and include ethynyl, propynyl, butynyl,
isobutynyl, hexynyl, and the like.
[0090] The term "aromatic" as used herein alone or as part of
another group denotes optionally substituted homo- or heterocyclic
conjugated planar ring or ring system comprising delocalized
electrons. These aromatic groups are preferably monocyclic (e.g.,
furan or benzene), bicyclic, or tricyclic groups containing from 5
to 14 atoms in the ring portion. The term "aromatic" encompasses
"aryl" groups defined below.
[0091] The terms "aryl" or "Ar" as used herein alone or as part of
another group denote optionally substituted homocyclic aromatic
groups, preferably monocyclic or bicyclic groups containing from 6
to 10 carbons in the ring portion, such as phenyl, biphenyl,
naphthyl, substituted phenyl, substituted biphenyl, or substituted
naphthyl.
[0092] The terms "carbocyclo" or "carbocyclic" as used herein alone
or as part of another group denote optionally substituted, aromatic
or non-aromatic, homocyclic ring or ring system in which all of the
atoms in the ring are carbon, with preferably 5 or 6 carbon atoms
in each ring. Exemplary substituents include one or more of the
following groups: hydrocarbyl, substituted hydrocarbyl, alkyl,
alkoxy, acyl, acyloxy, alkenyl, alkenoxy, aryl, aryloxy, amino,
amido, acetal, carbamyl, carbocyclo, cyano, ester, ether, halogen,
heterocyclo, hydroxy, keto, ketal, phospho, nitro, and thio.
[0093] The terms "halogen" or "halo" as used herein alone or as
part of another group refer to chlorine, bromine, fluorine, and
iodine.
[0094] The term "heteroatom" refers to atoms other than carbon and
hydrogen.
[0095] The term "heteroaromatic" as used herein alone or as part of
another group denotes optionally substituted aromatic groups having
at least one heteroatom in at least one ring, and preferably 5 or 6
atoms in each ring. The heteroaromatic group preferably has 1 or 2
oxygen atoms and/or 1 to 4 nitrogen atoms in the ring, and is
bonded to the remainder of the molecule through a carbon. Exemplary
groups include furyl, benzofuryl, oxazolyl, isoxazolyl,
oxadiazolyl, benzoxazolyl, benzoxadiazolyl, pyrrolyl, pyrazolyl,
imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl,
pyridazinyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl,
indazolyl, benzotriazolyl, tetrazolopyridazinyl, carbazolyl,
purinyl, quinolinyl, isoquinolinyl, imidazopyridyl, and the like.
Exemplary substituents include one or more of the following groups:
hydrocarbyl, substituted hydrocarbyl, alkyl, alkoxy, acyl, acyloxy,
alkenyl, alkenoxy, aryl, aryloxy, amino, amido, acetal, carbamyl,
carbocyclo, cyano, ester, ether, halogen, heterocyclo, hydroxy,
keto, ketal, phospho, nitro, and thio.
[0096] The terms "heterocyclo" or "heterocyclic" as used herein
alone or as part of another group denote optionally substituted,
fully saturated or unsaturated, monocyclic or bicyclic, aromatic or
non-aromatic groups having at least one heteroatom in at least one
ring, and preferably 5 or 6 atoms in each ring. The heterocyclo
group preferably has 1 or 2 oxygen atoms and/or 1 to 4 nitrogen
atoms in the ring, and is bonded to the remainder of the molecule
through a carbon or heteroatom. Exemplary heterocyclo groups
include heteroaromatics as described above. Exemplary substituents
include one or more of the following groups: hydrocarbyl,
substituted hydrocarbyl, alkyl, alkoxy, acyl, acyloxy, alkenyl,
alkenoxy, aryl, aryloxy, amino, amido, acetal, carbamyl,
carbocyclo, cyano, ester, ether, halogen, heterocyclo, hydroxy,
keto, ketal, phospho, nitro, and thio.
[0097] The terms "hydrocarbon" and "hydrocarbyl" as used herein
describe organic compounds or radicals consisting exclusively of
the elements carbon and hydrogen. These moieties include alkyl,
alkenyl, alkynyl, and aryl moieties. These moieties also include
alkyl, alkenyl, alkynyl, and aryl moieties substituted with other
aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl
and alkynaryl. Unless otherwise indicated, these moieties
preferably comprise 1 to 20 carbon atoms.
[0098] The term "oxygen protecting group" as used herein denotes a
group capable of protecting an oxygen atom (and hence, forming a
protected hydroxyl group), wherein the protecting group may be
removed, subsequent to the reaction for which protection is
employed, without disturbing the remainder of the molecule.
Exemplary oxygen protecting groups include ethers (e.g., allyl,
triphenylmethyl (trityl or Tr), p-methoxybenzyl (PMB),
p-methoxyphenyl (PMP)), acetals (e.g., methoxymethyl (MOM),
.beta.-methoxyethoxymethyl (MEM), tetrahydropyranyl (THP), ethoxy
ethyl (EE), methylthiomethyl (MTM), 2-methoxy-2-propyl (MOP),
2-trimethylsilylethoxymethyl (SEM)), esters (e.g., benzoate (Bz),
allyl carbonate, 2,2,2-trichloroethyl carbonate (Troc),
2-trimethylsilylethyl carbonate), silyl ethers (e.g.,
trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl
(TIPS), triphenylsilyl (TPS), t-butyldimethylsilyl (TBDMS),
t-butyldiphenylsilyl (TBDPS) and the like. A variety of oxygen
protecting groups and the synthesis thereof may be found in
"Greene's Protective Groups in Organic Synthesis," 4.sup.th Ed. by
P.G.M. Wuts and T.W. Greene, John Wiley & Sons, Inc., 2007.
[0099] The "substituted hydrocarbyl" moieties described herein are
hydrocarbyl moieties which are substituted with at least one atom
other than carbon, including moieties in which a carbon chain atom
is substituted with a heteroatom such as nitrogen, oxygen, silicon,
phosphorous, boron, or a halogen atom, and moieties in which the
carbon chain comprises additional substituents. These substituents
include alkyl, alkoxy, acyl, acyloxy, alkenyl, alkenoxy, aryl,
aryloxy, amino, amido, acetal, carbamyl, carbocyclo, cyano, ester,
ether, halogen, heterocyclo, hydroxy, keto, ketal, phospho, nitro,
and thio.
[0100] When introducing elements of the present invention or the
preferred embodiments(s) thereof, the articles "a", "an", "the" and
"said" are intended to mean that there are one or more of the
elements. The terms "comprising", "including" and "having" are
intended to be inclusive and mean that there may be additional
elements other than the listed elements.
[0101] Having described the invention in detail, it will be
apparent that modifications and variations are possible without
departing from the scope of the invention defined in the appended
claims.
EXAMPLES
[0102] The following examples are included to demonstrate certain
embodiments of the invention. It should be appreciated by those of
skill in the art that the techniques disclosed in the examples
represent techniques discovered by the inventors to function well
in the practice of the invention. Those of skill in the art should,
however, in light of the present disclosure, appreciate that many
changes can be made in the specific embodiments that are disclosed
and still obtain a like or similar result without departing from
the spirit and scope of the invention, therefore all matter set
forth is to be interpreted as illustrative and not in a limiting
sense.
Example 1: Preparation of 6.beta.-N-methylnaltrexamine (4)
##STR00005##
[0103] Preparation of 6.beta.-N-benzyl-N-methylnaltrexamine (3)
[0104] To a stirred solution of naltrexone (2) (9.15 g, 26.8 mmol)
in 250 ml of toluene were added N-benzylmethylamine (3.6 ml, 28
mmol) and p-toluenesulfonic acid monohydride (51 mg, 0.268 mmol).
The reaction flask was equipped with a Dean-Stark trap and was
refluxed for 17 hours. The toluene was removed and the crude
products were dissolved in 75 ml of methanol. NaBH.sub.3CN (2.1 g,
32.7 mmol) was then added to the resulting solution and the mixture
was stirred at 0.degree. C. After stirring for 2 h, LC-MS indicated
the reaction was completed. The solution was concentrated on rotary
evaporator. To the residue was added ethyl acetate then followed by
a saturated sodium bicarbonate solution. The organic phase was
separated and the aqueous phase was extracted with ethyl acetate
twice. The combined organic layer was washed successively with
saturated aqueous sodium bicarbonate solution, saturated aqueous
NaCl solution, dried over anhydrous sodium sulfate, and then
concentrated in vacuo to a residue. The residue was chromatographed
on silica gel with hexane/ethyl acetate as mobile phase providing
9.2 g of compound (3) as amorphous solid.
Preparation of 6.beta.-N-methylnaltrexamine (4)
[0105] To a Parr bottle were added
6.beta.-N-benzyl-N-methylnaltrexamine (3) (4.3 mmol), 10% Palladium
on Carbon (wetted with ca. 50% water, 190 mg), and glacial acetic
acid (30 mL). The Parr bottle was attached to the Parr
Hydrogenation Apparatus and flushed three times with nitrogen and
then with three times with hydrogen. The mixture was reacted for 24
hours at room temperature under a pressure of 35 psi of hydrogen. A
reaction aliquot was taken and LC-MS indicated the reaction was
complete. The Parr bottle was removed from the Parr Hydrogenation
Apparatus and the reaction mixture was filtered through celite. The
filtrate was concentrated. To the residue was added water (15 mL)
and the pH was then adjusted to 9 using 29% ammonia. The resulting
mixture was extracted with 1:9 methanol/chloroform, the organic
extracts were combined, and dried over anhydrous sodium sulfate.
The dried organic solution was concentrated in vacuo, the residue
was purified on silica gel column with methanol/DCM/Et.sub.3N
mixture as mobile phase, concentrating the collected fractions, and
dried under vacuo, providing 1.2 g of product. M+H.sup.+=357.47 on
LC-MS; .sup.1H NMR (CDCl.sub.3) .delta. ppm 6.65 (1H, d, J=8.0 Hz),
6.54 (1H, d, J=8.0 Hz), 4.53 (1H, d, J=8.0 Hz), 3.05-2.97 (2H, m),
2.64-2.54 (3H, m), 2.49 (s, 3H), 2.36 (d, 2H, J=4 Hz), 2.22-2.13
(m, 2H), 1.95-1.92 (1H, m), 1.67-1.60 (2H, m), 1.45-1.40 (2H, m),
0.84-0.81 (1H, m), 0.52 (2H, d, J=8 Hz), 0.12-0.11 (2H, m)
Example 2: Preparation of Compounds 5(a) and 5(b)
##STR00006##
[0106] Preparation of
17-Cyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.beta.-(1S,2S-
)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan.
Hydrochloride (5a)
[0107] To the mixture of 6.beta.-N-methylnaltrexamine (4) (0.5 g,
1.4 mmol), (1S,2S)-2-(3-furyl)cyclopropane-1-carboxylic acid (0.22
g, 1.4 mmol), DMF (5.0 mL) was added HATU
(1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxid hexafluorophosphate) (0.53 g, 1.4 mmol) and triethylamine
(0.39 mL, 2.8 mmol). The resulting yellow solution was stirred at
room temperature under nitrogen for two hours where LC-MS indicated
the reaction was done. To the reaction solution was added ethyl
acetate (70 mL). The resulting solution was washed with brine then
dried over anhydrous sodium sulfate. The dried organic phase was
concentrated on a rotary evaporator. The residue was purified on
silica gel eluting with a mixture of
Et.sub.3N/MeOH/CH.sub.2Cl.sub.2. The collected desired fractions
were concentrated under vacuum. The obtained oil product was
dissolved in ethyl acetate and this solution was cooled in ice
bath. To the cooled solution was added an equivalent of 1.0 N HCl
in ether. The resulting mixture was concentrated under vacuum to
provide 0.4 g off-white solid. M+H.sup.+=491.37 on LC-MS.
Preparation of
17-Cyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.beta.-((1R,2-
R)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan
Hydrochloride (5b)
[0108] To the mixture of 6.beta.-N-methylnaltrexamine (4) (0.5 g,
1.4 mmol), (1R, 2R)-2-(3-furyl)cyclopropane-1-carboxylic acid (0.22
g, 1.4 mmol), DMF (5.0 mL) was added HATU (0.53 g, 1.4 mmol) and
triethylamine (0.39 mL, 2.8 mmol). The resulting yellow solution
was stirred at room temperature under nitrogen for two hours where
LC-MS indicated the reaction was complete. To the reaction solution
was added ethyl acetate (70 mL) and the resulting solution was
washed with brine. The organic phase was dried over anhydrous
sodium sulfate. The dried organic phase was concentrated on a
rotary evaporator to a residue. The residue was purified on silica
gel eluting with a mixture of Et.sub.3N/MeOH/CH.sub.2Cl.sub.2. The
collected desired fractions were concentrated under vacuum. The
obtained oil product was dissolved in ethyl acetate and the
resulting solution was cooled in ice bath. To this solution was
added an equivalent of 1.0 N HCl in ether. The resulting mixture
was concentrated under vacuum to provide 0.5 g compound (3) as
off-white solid. M+H.sup.+=491.36 on LC-MS.
Example 3: Preparation of 6.alpha.-N-methylnaltrexamine (6)
##STR00007##
[0110] To the mixture of naltrexone HCl (2) (10.g, 26.5 mmol) and
THF (150 mL) was added a MeNH.sub.2 solution (2.0 N, 15 mL, 30
mmol). The resulting mixture was stirred at room temperature under
nitrogen for 30 minutes. Then, NaHB(OAc).sub.3 (12.3 g, 56.2 mmol)
was added over two hours. Then, the reaction was quenched by slowly
adding 1% HCl solution (60 mL). The solution was stirred at room
temperature for 15 minutes and the pH was adjusted to 8.5 with
NaHCO.sub.3 powder. The top organic phase was separated; the
aqueous phase was extracted with MeOH/CH.sub.2Cl.sub.2. The
combined organic extracts were dried over anhydrous sodium sulfate.
The dried organic solution was concentrated under vacuum. The
residue was further purified on silica gel column eluting with
MeOH/CH.sub.2Cl.sub.2/Et.sub.3N. The product was obtained as
off-white solid, M+H.sup.+=357.20 on LC-MS.
Example 4: Preparation of Compounds 7(a) and 7(b)
##STR00008##
[0111] Preparation of
17-Cyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.alpha.-((1S,-
2S)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan.
Hydrochloride (7a)
[0112] To the mixture of 6.alpha.-N-methylnaltrexamine (6) (0.5 g,
1.4 mmol), (1S,2S)-2-(3-furyl)cyclopropane-1-carboxylic acid (0.22
g, 1.4 mmol), DMF (5.0 mL) was added HATU (0.53 g, 1.4 mmol) and
triethylamine (0.39 mL, 2.8 mmol). The resulting yellow solution
was stirred at room temperature under nitrogen for two hours where
LC-MS indicated the reaction was complete. To the reaction solution
was added ethyl acetate (70 mL). The resulting solution was washed
with brine and the organic phase was dried over anhydrous sodium
sulfate. The dried organic phase was concentrated under vacuum and
the residue was purified on silica gel eluting with a mixture of
Et.sub.3N/MeOH/CH.sub.2Cl.sub.2. The collected desired fractions
were concentrated under vacuum. The obtained oil product was
dissolved in ethyl acetate and cooled in ice bath. To the cooled
solution was added equivalent of 1.0 N HCl in ether. The resulting
mixture was concentrated under vacuum to provide 0.3 g off-white
solid. M+H.sup.=491.24 on LC-MS.
Preparation of
17-Cyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.alpha.-((1R,-
2R)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan.
Hydrochloride (7b)
[0113] To the mixture of 6.alpha.-N-methylnaltrexamine (6) (0.5 g,
1.4 mmol), (1R,2R)-2-(3-furyl)cyclopropane-1-carboxylic acid (0.22
g, 1.4 mmol), DMF (5.0 mL) was added HATU (0.53 g, 1.4 mmol) and
triethylamine (0.39 mL, 2.8 mmol). The resulting yellow solution
was stirred at room temperature under nitrogen for two hours where
LC-MS indicated the reaction was complete. To the reaction solution
was added ethyl acetate (70 mL). The resulting solution was washed
with brine and the organic phase was dried over anhydrous sodium
sulfate. The dried organic phase was concentrated on a rotary
evaporator and the residue was purified on silica gel eluting with
a mixture of Et.sub.3N/MeOH/CH.sub.2Cl.sub.2. The collected desired
fractions were concentrated under vacuum. The obtained oil product
was dissolved in ethyl acetate and cooled in ice bath. To the
cooled solution was added equivalent of 1.0 N HCl in ether. The
resulting mixture was concentrated under vacuum to provide 0.35 g
off-white solid. M+H.sup.+=491.38 on LC-MS.
Example 5: Synthesis of
17-(1-hydroxycyclopropanemethyl)-4,5.alpha.-expoy-6.beta.-methylamino-3,1-
4.beta.-dihydroxymorphinan (12)
##STR00009##
[0114] Synthesis of
17-(1-acetoxycyclopropanecarboxamido)-3-benzoxy-4,5.alpha.-expoy-6-oxo-14-
.beta.-hydroxymorphinan (9)
[0115] To a three-neck reaction flask under nitrogen was placed
starting material (8) (14.0 g, 37.1 mmol), followed by adding
dichloromethane (150 mL), and triethylamine (22.40 g, 221 mmol);
the resulting mixture was cooled in ice bath, to the cold reaction
was added acyl chloride (17.6 g, 122.1 mmol). After finishing
addition, ice bath was removed; the reaction was stirred at room
temperature for 4 hours; LC-MS analysis indicated the reaction was
completed; the reaction was placed in ice bath, then water (200 mL)
was added slowly to quench the reaction; the pH of the reaction
mixture was adjusted to 4-5 with dilute hydrogen chloride. The
organic phase was separated, the aqueous phase was extracted with
dichloromethane (250 mL.times.3). The combined organic extracts
were dried over anhydrous sodium sulfate. After filtration, the
dried organic phase was concentrated under vacuum; it provided a
dark yellow solid, 10.18 g, [M+H].sup.+=504.6 on LC-MS.
Synthesis of
17-(1-acetoxycyclopropanecarboxamido)-3-benzoxy-4,5.alpha.-expoy-6.beta.--
benzyl(methyl)amino-14.beta.-hydroxymorphinan (10)
[0116] To a three-neck reaction flask was placed the intermediate
(9) (5.0 g, 9.9 mmol) and benzene (100 mL); to the resulting
solution was added benzoic acid (1.21 g, 9.9 mmol) and
benzylmethylamine (2.41 g, 19.8 mmol). The resulting mixture was
heated to refluxing with azeotropic distillation for 24 hours.
Then, the reaction was cooled to room temperature. To the reaction
was added methanol (20 mL), followed by adding sodium cyano
borohydride (0.94 g, 15.0 mmol). The reaction was stirred at room
temperature for 2 hours. LC-MS analysis indicated the reaction was
complete. To the reaction was added water (20 mL) and saturated
sodium hydrogen carbonate solution (100 mL). The product was
extracted with ethyl acetate (3.times.100 mL). The combined organic
extracts were washed with brine (200 mL) and dried over anhydrous
sodium sulfate. After filtration, the dried organic solution was
concentrated under vacuum; the crude material was further purified
on silica gel column with a mixture of ethyl
acetate/hexane/methanol/triethylamine. Concentration of the
collected fractions under vacuum provided an oil material, 6.0 g,
[M+H].sup.+=609.7 on LC-MS.
Synthesis of
17-(1-hydroxycyclopropanemethyl)-3-benzoxy-4,5.alpha.-expoy-6.beta.-benzy-
l(methyl)amino-14.beta.-hydroxymorphinan (11)
[0117] In a three-neck reaction flask under nitrogen was placed
intermediate (10) (6.0 g, 9.86 mmol) and THF. To the resulting
solution was added LiAlH.sub.4 (1.50 g, 39.5 mmol), the reaction
was heated to reflux for 2-4 hours; LC-MS analysis indicated the
reaction was completed. The reaction was cooled to room
temperature, then reaction was dumped into an ice/water mixture
(150 mL); to the mixture was then added 20% sodium hydroxide
solution (2 mL), followed by added ethyl acetate (150 mL). The
organic phase was separated and the aqueous phase was extracted
with ethyl acetate (2.times.150 mL). The combined organic extracts
were filtered through diatomaceous earth; the organic filtrate was
separated and dried over anhydrous sodium sulfate. After
filtration, the dried organic phase was concentrated under vacuum.
The crude material was further purified on silica gel column with a
mixture of ethyl acetate/hexane/methanol/triethylamine,
concentration of the collected fractions under vacuum provided an
oil material, 3.16 g; [M+H].sup.+=553.7 on LC-MS. .sup.1H NMR (400
MHz, CDCl.sub.3): 0.43-0.48 (2H, m), 0.82-0.87 (2H, m), 1.30-1.70
(4H, m), 1.95-2.8 (1H, m), 2.15-2.32 (2H, m), 2.35 (3H, s), 2.53
(1H, d, J=12.8 Hz), 2.60-2.70 (2H, m), 2.75 (1H, d, J=12.8 Hz),
2.72-2.82 (1H, m), 2.97-3.8 (2H, m), 3.72 (1H, d, J=13.6 Hz), 3.81
(1H, d, J=13.6 Hz), 4.77 (1H, d, J=7.6 Hz), 5.22 (2H, s), 6.53 (1H,
d, J=8.0 Hz), 6.73 (1H, d, J=8.0 Hz), 7.15-7.51 (10H).
Synthesis of
17-(1-hydroxycyclopropanemethyl)-4,5.alpha.-expoy-6.beta.-methylamino-3,1-
4.beta.-dihydroxymorphinan (12)
[0118] To the hydrogenation reaction flask was added intermediate
(11) (3.16.0 g, 5.72 mmol and methanol (30 mL), followed by adding
phthalic acid (1.9 g, 11.4 mmol) and 10% Pd/C (2.36 g). The
reaction was carried out under hydrogen atmosphere at room
temperature for 24 hours. LC-MS analysis indicated the reaction was
complete. The reaction was filtered through diatomaceous earth and
the filtrate was concentrated under vacuum to provide a grey solid,
3.38 g. [M+H].sup.+=373.5 on LC-MS.
Example 6: Preparation of
17-(1-hydroxycyclopropanemethyl)-4,5.alpha.-expoy-6.alpha.-methylamino-3,-
14.beta.-dihydroxymorphinan (15)
##STR00010##
[0119] Synthesis of
17-(1-acetoxycyclopropanecarboxamido)-3-benzoxy-4,5.alpha.-expoy-6.alpha.-
-benzyl(methyl)amino-14.beta.-hydroxymorphinan (13)
[0120] To a three-neck round bottom flask were added intermediate
(9) (3.0 g, 5.96 mmol) and methanol (10 mL), followed by adding 30%
methylamine in methanol (2.4 g, 23.1 mmol), and acetic acid (0.1
mL). The resulting mixture was stirred at room temperature for 2
hours and then the reaction was placed in ice bath. Sodium
cyanoborohydride (1.5 g, 23.9 mmol) was added. The ice bath was
removed and the reaction was stirred at room temperature for 24
hours. LC-MS analysis indicated the reaction was complete. To the
reaction was added water (50 mL) and followed by adding ethyl
acetate (150 mL). The mixture's pH was adjusted to .about.8 with
saturated sodium bicarbonate solution. The organic phase was
separated and the aqueous phase was extracted with ethyl acetate
(150 mL.times.2). The combined organic extracts were dried over
anhydrous sodium sulfate. Concentrating the dried organic extracts
under vacuum provided a solid, 3.15 g. [M+H].sup.+=519.6 on
LC-MS.
Synthesis of
17-(1-hydroxycyclopropanemethyl)-3-benzoxy-4,5.alpha.-expoy-6.alpha.-meth-
ylamino-14.beta.-hydroxymorphinan (14)
[0121] In a three-neck reaction flask under nitrogen was placed
intermediate (13) (3.15 g, 6.07 mmol) and THF (30 mL). To the
resulting solution was added LiAlH.sub.4 (0.69 g, 18.2 mmol); the
reaction was heated to reflux for 2-4 hours; LC-MS analysis
indicated the reaction was completed. The reaction was cooled to
room temperature and then poured into an ice/water mixture (100
mL). To the mixture was then added 20% sodium hydroxide solution
(1.5 mL) followed by added ethyl acetate (100 mL). The organic
phase was separated and the aqueous phase was extracted with ethyl
acetate (2.times.100 mL). The combined organic extracts were
filtered through diatomaceous earth, the organic filtrate was
separated, and dried over anhydrous sodium sulfate. After
filtration, the dried organic phase was concentrated under vacuum
to provide an oil. 1.98 g; [M+H].sup.+=463.6 on LC-MS.
Synthesis of
17-(1-hydroxycyclopropanemethyl)-4,5.alpha.-expoy-6.alpha.-methylamino-3,-
14.beta.-dihydroxymorphinan (15)
[0122] To the hydrogenation reaction flask under nitrogen was
placed intermediate (14) (3.16.0 g, 5.72 mmol) and methanol (30
mL), followed by adding phthalic acid (1.42 g, 8.54 mmol) and 10%
Pd/C (1.78 g). The reaction was then carried out under hydrogen
atmosphere at room temperature for 24 hours. LC-MS analysis
indicated the reaction was complete. The reaction was filtered
through diatomaceous earth and was concentrated under vacuum to
provide a grey solid, 2.72 g. [M+H].sup.+=373.5 on LC-MS.
Example 7: Preparation of Compounds 16(a) and 16(b)
##STR00011##
[0123] Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.a-
lpha.-((1S,2S)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan
trifluoroacetate (16a)
[0124] To the three-neck reaction flask under nitrogen at room
temperature were added (1S,2S)-2-(3-furyl)cyclopropane-1-carboxylic
acid (20 mg, 0.134 mmol), intermediate (15) (50 mg, 0.134 mmol) and
THF (1.0 mL); after the solid was dissolved under stirring, DEPBT
(3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one) (80 mg,
0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was complete. The solvent was removed under
vacuum. To the residue was added dichloromethane (2.0 mL). The
resulting solution was washed with 5% NaHSO.sub.4 aqueous solution
(2.0 mL.times.3), 5% aqueous NaHCO.sub.3 solution (2.0 mL.times.3),
and brine (2.0 mL.times.3). The organic phase was dried over
anhydrous sodium sulfate and filtered. The filtrate was then
concentrated under vacuum. The residue was further purified on
reverse phase LC with mobile phase (A:0.01% TFA/H.sub.2O, B:100%
ACN). The collected fractions were combined and the product was
obtained as white powder after lyophilization, 10 mg, yield=14.7%.
[M+H].sup.+=507.6 on LC-MS.
Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.a-
lpha.-((1R,2R)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (16b)
[0125] To the three-neck reaction flask under nitrogen at room
temperature were added (1R,2R)-2-(3-furyl)cyclopropane-1-carboxylic
acid (20 mg, 0.134 mmol), intermediate (15) (50 mg, 0.134 mmol) and
THF (1.0 mL); after the solid was dissolved under stirring, DEPBT
(80 mg, 0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were
added. The reaction was stirred at room temperature overnight.
LC-MS analysis indicated the reaction was complete and the solvent
was removed under vacuum. To the residue was added dichloromethane
(2.0 mL). The resulting solution was washed with 5% aqueous
NaHSO.sub.4 solution (2.0 mL.times.3), 5% aqueous NaHCO.sub.3
solution (2.0 m.times.3 L), and brine (2.0 mL.times.3). The organic
phase was dried over anhydrous sodium sulfate and filtered. The
filtrate was then concentrated under vacuum, the residue was
further purified on preparation LC with mobile phase (A:0.01%
TFA/H2O, B:100% ACN). The collected fractions were combined; the
product was obtained as white powder after lyophilization: 14 mg,
yield=20.6%. M+H.sup.+=507.6 on LC-MS.
Example 8: Preparation of Compounds 17(a) and 17(b)
##STR00012##
[0126] Preparation of
17-(1-hydroxylcyclopropylmethyl)-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.-
beta.-((1S,2S)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (17a)
[0127] To the three-neck reaction flask under nitrogen at room
temperature was added (1S,2S)-2-(3-furyl)cyclopropane-1-carboxylic
acid (20 mg, 0.134 mmol), intermediate (12) (50 mg, 0.134 mmol) and
THF (1.0 mL); after the solid was dissolved under stirring, DEPBT
(80 mg, 0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were
added. The reaction was stirred at room temperature overnight.
LC-MS analysis indicated the reaction was complete. The solvent was
removed under vacuum. To the residue was added dichloromethane (2.0
mL), the resulting solution was washed with 5% aqueous NaHSO.sub.4
solution (2.0 mL.times.3), 5% aqueous NaHCO.sub.3 solution (2.0
mL.times.3), and brine (2.0 mL.times.3). The organic phase was
dried over anhydrous sodium sulfate. The filtrate was then
concentrated under vacuum and the residue was further purified on
preparation LC with mobile phase (A:0.01% TFA/H2O, B:100% AC). The
collected fractions were combined; the product was obtained as
white powder after lyophilization, 14 mg, yield=20.6%.
[M+H].sup.+=507.6 on LC-MS.
Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.b-
eta.-((1R,2R)--N-methyl-2-(3-furyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (17b)
[0128] To the three-neck reaction flask under nitrogen at room
temperature were added (1R,2R)-2-(3-furyl)cyclopropane-1-carboxylic
acid (20 mg, 0.134 mmol), intermediate (12) (50 mg, 0.134 mmol) and
THF (1.0 mL); after the solid was dissolved under stirring, DEPBT
(80 mg, 0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were
added. The reaction was stirred at room temperature overnight.
LC-MS analysis indicated the reaction was complete. The solvent was
removed under vacuum. To the residue was added dichloromethane (2.0
mL), the resulting solution was washed with 5% aqueous NaHSO.sub.4
solution (2.0 mL.times.3), 5% aqueous NaHCO.sub.3 solution (2.0
mL.times.3), and brine (2.0 mL.times.3). The organic phase was
dried over anhydrous sodium sulfate and filtered. The filtrate was
then concentrated under vacuum and the residue was further purified
on preparation LC with mobile phase (A:0.01% TFA/H.sub.2O, B:100%
ACN). The collected fractions were combined; the product was
obtained as white powder after lyophilization yielding a white
powder, 21 mg, yield=30.9%. [M+H].sup.+=507.6 on LC-MS.
Example 9: Preparation of Compounds 18(a) and 18(b)
##STR00013##
[0129] Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.a-
lpha.-((1S,2S)--N-methyl-2-(3-thienyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (18a)
[0130] To the three-neck reaction flask under nitrogen at room
temperature were added
(1S,2S)-2-(3-thienyl)cyclopropane-1-carboxylic acid (22.5 mg, 0.134
mmol), intermediate (15) (50 mg, 0.134 mmol) and THF (1.0 mL);
after the solid was dissolved under stirring, DEPBT (80 mg, 0.268
mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was complete and the solvent was removed
under vacuum. To the residue was added dichloromethane (2.0 mL) and
the resulting solution was washed with 5% aqueous NaHSO.sub.4
solution (2.0 mL), 5% aqueous NaHCO.sub.3 solution (2.0 mL), and
brine (2.0 mL.times.3). The organic phase was dried over anhydrous
sodium sulfate and filtered. The filtrate was then evaporated under
vacuum and the residue was further purified on preparation LC with
mobile phase (A:0.01% TFA/H.sub.2O, B:100% ACN). The collected
fractions were combined; the product was obtained as white powder
after lyophilization, 15 mg, yield=21.4%. [M+H].sup.+=523.7 on
LC-MS.
Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.a-
lpha.-((1R,2R)--N-methyl-2-(3-thienyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (18b)
[0131] To the three-neck reaction flask under nitrogen at room
temperature were added
(1R,2R)-2-(3-thienyl)cyclopropane-1-carboxylic acid (22.5 mg, 0.134
mmol), intermediate (15) (50 mg, 0.134 mmol) and THF (1.0 mL);
after the solid was dissolved under stirring, DEPBT (80 mg, 0.268
mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was done. The solvent was removed under
vacuum. To the residue was added dichloromethane (2.0 mL), the
resulting solution was washed with 5% aqueous NaHSO.sub.4 solution
(2.0 mL), 5% aqueous NaHCO.sub.3 solution (2.0 mL), and brine (2.0
mL.times.3). The organic phase was dried over anhydrous sodium
sulfate and filtered. The filtered organic phase was then
evaporated under vacuum. The residue was further purified on
preparation LC with mobile phase (A:0.01% TFA/H.sub.2O, B:100%
ACN). The collected fractions were combined; the product was
obtained as white powder after lyophilization, 6.5 mg, yield=9.3%.
[M+H].sup.+=523.7 on LC-MS.
Example 10: Preparation of Compounds 19(a) and 19(b)
##STR00014##
[0132] Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.b-
eta.-((1S,2S)--N-methyl-2-(3-thienyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (19a)
[0133] To the three-neck reaction flask under nitrogen at room
temperature were added
(1S,2S)-2-(3-thienyl)cyclopropane-1-carboxylic acid (22.5 mg, 0.134
mmol), intermediate 12 (50 mg, 0.134 mmol) and THF (1.0 mL); after
the solid was dissolved under stirring, DEPBT (80 mg, 0.268 mmol)
and triethylamine (27 mg, 0.268 mmol) were added. The reaction was
stirred at room temperature overnight. LC-MS analysis indicated the
reaction was complete. The solvent was removed under vacuum. To the
residue was added dichloromethane (2.0 mL). The resulting solution
was washed with 5% aqueous NaHSO.sub.4 solution (2.0 mL), 5%
aqueous NaHCO.sub.3 solution (2.0 mL), and brine (2.0 mL.times.3).
The organic phase was dried over anhydrous sodium sulfate and
filtered. The filtrate was then concentrated under vacuum. The
residue was further purified on reverse phase LC with mobile phase
(A:0.01% TFA/H.sub.2O, B:100% ACN). The collected fractions were
combined; the product was obtained as white powder after
lyophilization, 13 mg, yield=18.5%. [M+H].sup.+=523.7 on LC-MS.
Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5a-epoxy-3,14.beta.-dihydroxy-6.beta.-(-
(1R,2R)--N-methyl-2-(3-thienyl)-cyclopropanecarboxamido)morphinan.
trifluoroacetate (19b)
[0134] To the three-neck reaction flask under nitrogen at room
temperature were added
(1R,2R)-2-(3-thienyl)cyclopropane-1-carboxylic acid (22.5 mg, 0.134
mmol), intermediate 12 (50 mg, 0.134 mmol) and THF (1.0 mL); after
the solid was dissolved under stirring, DEPBT (80 mg, 0.268 mmol)
and triethylamine (27 mg, 0.268 mmol) were added. The reaction was
stirred at room temperature overnight. LC-MS analysis indicated the
reaction was complete. The solvent was removed under vacuum. To the
residue was added dichloromethane (2.0 mL), the resulting solution
was washed with 5% aqueous NaHSO.sub.4 solution (2.0 mL.times.3),
5% aqueous NaHCO.sub.3 solution (2.0 mL.times.3), and brine (2.0
mL.times.3). The organic phase was dried over anhydrous sodium
sulfate and filtered. The filtrate was then evaporated under
vacuum. The residue was further purified on preparation LC with
mobile phase (A:0.01% TFA/H.sub.2O, B:100% ACN). The collected
fractions were combined; the product was obtained as white powder
after lyophilization, 14 mg, yield=20.0%. [M+H].sup.+=523.7 on
LC-MS.
Example 11: Preparation of Compounds 20(a) and 20(b)
##STR00015##
[0135] Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.a-
lpha.-((1S,2S)--N-methyl-2-(3-(4-hydroxylphenyl)-cyclopropanecarboxamido)
morphinan. trifluoroacetate (20a)
[0136] To the three-neck reaction flask under nitrogen at room
temperature were added
(1S,2S)-2-(3-thienyl)cyclopropane-1-carboxylic acid (23.9 mg, 0.134
mmol), intermediate (15) (50 mg, 0.134 mmol) and THF (1.0 mL);
after the solid was dissolved under stirring, DEPBT (80 mg, 0.268
mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was complete. The solvent was removed under
vacuum. To the residue was added dichloromethane (2.0 mL), the
resulting solution was washed with 5% aqueous NaHSO.sub.4 solution
(2.0 mL), 5% aqueous NaHCO.sub.3 solution (2.0 mL), and brine (2.0
mL.times.3). The organic phase was dried over anhydrous sodium
sulfate and filtered. The filtrate was then concentrated under
vacuum and the obtained residue was further purified on preparation
LC with mobile phase (A:0.01% TFA/H.sub.2O, B:100% ACN). The
collected fractions were combined; the product was obtained as
white powder after lyophilization, 16 mg, yield=22.4%.
[M+H].sup.+=533.6 on LC-MS.
Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.a-
lpha.-((1R,2R)--N-methyl-2-(3-(4-hydroxylphenyl)-cyclopropanecarboxamido)m-
orphinan trifluoroacetate (20b)
[0137] To the three-neck reaction flask under nitrogen at room
temperature were added
(1R,2R)-2-(3-(4-hydroxylphenyl)cyclopropane-1-carboxylic acid (23.9
mg, 0.134 mmol), intermediate (15) (50 mg, 0.134 mmol) and THF (1.0
mL); after the solid was dissolved under stirring, DEPBT (80 mg,
0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was complete. The solvent was removed under
vacuum. To the residue was added dichloromethane (2.0 mL), the
resulting solution was washed with 5% aqueous NaHSO.sub.4 solution
(2.0 mL.times.2), 5% aqueous NaHCO.sub.3 solution (2.0 mL.times.2),
and brine (2.0 mL.times.3). The organic phase was dried over
anhydrous sodium sulfate and filtered. The filtrate was then
concentrated under vacuum. The residue was further purified on
reverse phase LC with mobile phase (A: 0.01% TFA/H.sub.2O, B: 100%
ACN). The collected fractions were combined; the product was
obtained as white powder after lyophilization, 13 mg, yield=18.2%.
[M+H].sup.+=533.6 on LC-MS.
Example 12: Preparation of Compounds 21(a) and 21(b)
##STR00016##
[0138] Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.b-
eta.-((1S,2S)--N-methyl-2-(3-(4-hydroxylphenyl)-cyclopropanecarboxamido)
morphinan trifluoroacetate (21a)
[0139] To the three-neck reaction flask under nitrogen at room
temperature were added
(1S,2S)-2-(3-(4-hydroxylphenyl)cyclopropane-1-carboxylic acid (23.9
mg, 0.134 mmol), intermediate (12) (50 mg, 0.134 mmol) and THF (1.0
mL); after the solid was dissolved under stirring, DEPBT (80 mg,
0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was complete. The solvent was removed under
vacuum. To the residue was added dichloromethane (2.0 mL), the
resulting solution was washed with 5% aqueous NaHSO.sub.4 solution
(2.0 mL), 5% aqueous NaHCO.sub.3 aqueous solution (2.0 mL), and
brine (2.0 mL.times.3). The organic phase was dried over anhydrous
sodium sulfate and filtered. The filtrate was then evaporated under
vacuum, the residue was further purified on preparation LC with
mobile phase (A: 0.01% TFA/H.sub.2O, B: 100% ACN). The collected
fractions were combined; the product was obtained as white powder
after lyophilization, 11 mg, yield=15.4%. [M+H].sup.+=533.6 on
LC-MS.
Preparation of
17-(1-hydroxylcyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.b-
eta.-((1R,2R)--N-methyl-2-(3-(4-hydroxylphenyl)-cyclopropanecarboxamido)mo-
rphinan trifluoroacetate (21b)
[0140] To the three-neck reaction flask under nitrogen at room
temperature was added
(1R,2R)-2-(3-(4-hydroxylphenyl)cyclopropane-1-carboxylic acid (23.9
mg, 0.134 mmol), intermediate (12) (50 mg, 0.134 mmol) and THF (1.0
mL); after the solids were dissolved under stirring, DEPBT (80 mg,
0.268 mmol) and triethylamine (27 mg, 0.268 mmol) were added. The
reaction was stirred at room temperature overnight. LC-MS analysis
indicated the reaction was complete. The solvent was removed under
vacuum. To the residue was added dichloromethane (2.0 mL), the
resulting solution was washed with 5% aqueous NaHSO.sub.4 solution
(2.0 mL.times.3), 5% aqueous NaHCO.sub.3 solution (2.0 mL.times.3),
and brine (2.0 mL.times.3). The organic phase was dried over
anhydrous sodium sulfate and filtered. The filtrate was then
evaporated under vacuum. The residue was further purified on
preparation LC with mobile phase (A: 0.01% TFA/H.sub.2O, B: 100%
ACN). The collected fractions were combined; the product was
obtained as white powder after lyophilization, 10 mg, yield=14.0%.
[M+H].sup.+=533.6 on LC-MS.
Example 13: Preparation of Compounds 23(a) and 23(b)
##STR00017##
[0141] Preparation of
17-cyclopropylmethyl-10-oxo-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.beta.-
-((1S,2S)--N-methyl-2-(3-(4-hydroxylphenyl)-cyclopropanecarboxamido)morphi-
nan. hydrochloride (23a)
[0142] To the mixture of intermediate (22) (prepared based on
literature method (Chem. Pharm. Bull. 2004, 52(6), 664-669) (0.5 g,
1.4 mmol), (1S,2S)-2-(3-furyl)cyclopropane-1-carboxylic acid (0.22
g, 1.4 mmol), DMF (5.0 mL) was added HATU
(1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxid hexafluorophosphate) (0.53 g, 1.4 mmol) and triethylamine
(0.39 mL, 2.8 mmol). The resulting yellow solution was stirred at
room temperature under nitrogen until LC-MS analysis indicated the
reaction was complete. To the reaction solution was added ethyl
acetate (70 mL). The resulting solution was washed with brine,
dried over anhydrous sodium sulfate, and then filtered. The dried
organic phase was concentrated under vacuum. The residue was
purified on silica gel eluting with a mixture of
Et.sub.3N/MeOH/CH.sub.2Cl.sub.2. The collected desired fractions
were concentrated under vacuum. The obtained oil product was
dissolved in ethyl acetate and this solution was cooled in ice
bath. To the cooled solution was added an equivalent of 1.0 N HCl
in ether. The resulting mixture was concentrated under vacuum to
provide 0.14 g off-white solid. [M+H].sup.+=505.37 on LC-MS.
Preparation of
17-cyclopropylmethyl-10-oxo-4,5.alpha.-epoxy-3,14.beta.-dihydroxy-6.beta.-
-((1R,2R)--N-methyl-2-(3-(4-hydroxylphenyl)-cyclopropanecarboxamido)morphi-
nan hydrochloride (23b)
[0143] To the mixture of intermediate (22) (prepared based on
literature method (Chem. Pharm. Bull. 2004, 52(6) 664-669)(0.5 g,
1.4 mmol), (1R,2R)-2-(3-furyl)cyclopropane-1-carboxylic acid (0.22
g, 1.4 mmol), DMF (5.0 mL) was added HATU
(1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxid hexafluorophosphate) (0.53 g, 1.4 mmol) and triethylamine
(0.39 mL, 2.8 mmol). The resulting yellow solution was stirred at
room temperature under nitrogen until LC-MS analysis indicated the
reaction was complete. To the reaction solution was added ethyl
acetate (70 mL). The resulting solution was washed with brine,
dried over anhydrous sodium sulfate, and then filtered. The dried
organic phase was concentrated under vacuum. The residue was
purified on silica gel eluting with a mixture of
Et.sub.3N/MeOH/CH.sub.2Cl.sub.2. The collected desired fractions
were concentrated under vacuum. The obtained oil product was
dissolved in ethyl acetate and this solution was cooled in ice
bath. To the cooled solution was added an equivalent of 1.0 N HCl
in ether. The resulting mixture was concentrated under vacuum to
provide 0.25 g off-white solid. [M+H].sup.+=505.38 on LC-MS.
Example 14: Opioid Receptor Binding Assay
[0144] The measurement of opioid receptor binding affinity was
conducted using a radioligand binding assay on the membranes
prepared from HEK293 cells (human embryonic kidney cell line) that
were heterologously expressed for the recombinant human mu, delta
or kappa opioid receptors.
[0145] The assay buffers used for opioid receptor binding studies
were 50 mM Tris.HCl (pH 7.4) for KOR, 50 mM Tris.HCl (pH 7.4) with
5 mM MgCl.sub.2 for MOR, and 50 mM Tris.HCl (pH 7.4) with 10 mM
MgCl.sub.2 plus 1 mM EDTA for DOR. Wash buffer was containing 50 mM
Tris.HCl with pH 7.4.
[0146] The opioid receptor binding affinity were compared to three
known standards: Naltrindole, U-50488
(trans-(+)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]phenylac-
etamide, see M. Doi, T. Ishida and M, Inoue; Structure of
K-agonist, U-50488 Acta Cryst. (1990). C46, 676-678), and DAMGO
(D-Ala2 MePhe4, Gly(ol)5]encephalin, see Allan D. Blake, George
Bot, John C. Freeman, and Terry Reisine.dagger-dbl. Differential
Opioid Agonist Regulation of the Mouse m Opioid Receptor* THE
JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 272, No. 2, Issue of January
10, pp. 782-790, 1997).
[0147] The radio ligands were prepared at the final concentration
of 0.5 nM for [.sup.3H]DAMGO, 0.5 nM for [.sup.3H]diprenorphine,
and 0.5 nM for [.sup.3H] DADLE, which were used as the competing
radioligands for mu, kappa and delta receptor respectively.
[0148] Cell membrane of HEK293 cells transfected with opioid
receptors was prepared in the amount of 20 ug of MOR, 6.7 ug of KOR
and 6.7 ug of DOR per each well respectively. These membranes
containing the receptor of interest were incubated with increasing
concentrations of test compound in the presence of a single
concentration of radioligand. The fixed concentration of the
radioligand was used and serial dilutions of the test compound were
prepared.
[0149] Testing started at 10 uM of testing compound to 4-fold
serial dilution for 8-points detection. Transfer 1 .mu.l of
compounds/high control/low control to the 96 well plates according
to the plate map, then dispense 100 .mu.l of membrane stock
solution into the plate, add 100 .mu.l of radio ligand solution.
Incubation was carried out for 1 hour at room temperature with 300
rpm gentle agitation. Then, soaked the Unifilter-96 GF/C filter
plates with 50 .mu.l of 0.3% Poly ethyleneimine per well for at
least 0.5 hour at room temperature, and filtered the reaction
mixture through the plates using FilterMate.TM. harvester, then
wash each plate for four times with cold wash buffer. The filter
plates are then dried for 1 hour at 50.degree. C. After drying, the
filter was sealed in polyethylene and adds 50 .mu.l of Perkin Elmer
Microscint 20 cocktail and the radioactivity counted in a Perkin
Elmer MicroBeta2 counter.
[0150] Specific binding is determined by subtraction of the Bound
CPM values in the presence of 50-100.times. excess of cold ligand.
Data is fitted using the saturation analysis non-linear curve
fitting routines in Prism.RTM.. Calculate the inhibition using
following equation:
% Inhibition=(1-(Assay
well-Average_LC)/(Average_HC-Average_LC))*100%
[0151] Binding data are analyzed using GraphPad Prism 5.0 and
IC.sub.50 is generated by non-linear regression from dose response
curves. Use the model "log (inhibitor) vs. response--Variable
slope" to fit the data. This data is shown in Table 1.
TABLE-US-00001 TABLE 1 Binding Affinity Kappa Mu Delta IC.sub.50
IC.sub.50 IC.sub.50 Selectivity # Compounds (nM) (nM) (nM) .mu./k
.delta./k 1 U-50488 14.59 -- -- -- -- 2 DAMGO -- 0.68 -- -- -- 3
Naltrindole -- -- 0.18 -- -- 4 5a 0.42 10.73 86.46 1.76 207.59 5 5b
7.76 3.47 69.01 0.45 8.90 6 7a 0.05 0.3 0.66 5.85 12.6 7 7b 0.24
0.52 0.68 2.16 2.82 8 16a 0.94 1.55 5.46 1.65 5.80 9 16b 6.74 7.18
34.05 1.07 5.05 10 17a 1.22 4.96 43.07 4.07 35.3 11 17b 6.49 45.37
71.58 6.99 11.0 12 18a 0.97 1.58 10.93 1.63 11.3 13 18b 6.15 76.83
118.0 12.5 19.2 14 19a 0.17 1.37 16.34 8.05 96.1 15 19b 0.46 5.98
146.8 13.0 319 16 20a 102.3 119.3 160.9 1.12 1.57 17 20b 16.02 8.08
11.76 0.50 0.73 18 21a 0.85 1.25 30.23 1.47 35.6 19 21b >200
114.2 385 <0.57 <1.93 20 23a 0.070 12.2 261.2 174.3 3731 21
23b 0.62 73.71 528.2 118.9 1331
[0152] As the data in the above table indicated, the compounds 5a,
5b, 7a, 7b, 18a, 19a, and 21a provided better IC.sub.50 then
U-50488.
Example 15: FLIPR Calcium Assay in Whole Cells
[0153] The FLIPR Calcium Assay is used to measure the ability of an
opioid ligand to induce a functional response upon receptor
binding.
[0154] The MOR, DOR and KOR are G-protein coupled receptors (GPCRs)
which play an important role in cell signaling. The receptor is
activated by a ligand then triggering G-protein activation inside
the cell. An activated G-protein induces various cascades of
intracellular messengers including calcium flux. The functional
cell-based assays evaluated the changes of intracellular calcium
level which were detected through use of fluorescent
calcium-sensitive reporter dyes. The basic system of performing a
calcium mobilization assay includes the FLIPR Calcium Assay Kit and
the FLIPR Tetra.RTM. System, which were used to observe changes in
intracellular calcium levels and determine the dose-response in
HEK293 cells transfected with the recombinant human mu, delta or
kappa opioid receptors.
[0155] The cells used in the assay were grown in the culture medium
of 88% DMEM which contains 10% FBS, 300 ug/mL G418, 2 ug/mL
Blasticidin, 1% GlutaMax and 1% Penicillin/Streptomycin
(Hyclone-SV30010). Seeded 20000 cells in 20 uL medium to each well
of assay plate (Greiner-781946), and the cells were maintained at
37.degree. C. in an incubator with 5% CO.sub.2 for 20 hours. The
compound was then prepared at 5-fold serial dilution to get 10
doses and 500 nL of each concentration was transferred to compound
plate. Then 30 uL assay buffer (20 mM HEPES and 1.times.HBSS) was
added to each well of compound plate; the plate was spin at 1500
rpm for 15 seconds. Then 20 uL of 2.times.Fluo-4 Direct.TM. No-wash
Loading Buffer ((Invitrogen-F10471) was gently dispensed to each
well of assay plate and was spin at 1000 rpm for 15 s, incubated at
37.degree. C. for 50 min. The assay plate was removed from the
incubator and placed at room temperature for 10 min. Then, the
assay plate, compound plate and tip box were placed directly into
the FLIPR Tetra.RTM. System. 10 uL compound was transferred from
compound plate to the assay plate in FLIPR Tetra Fluorometric
Imaging Plate Reader and plate was for 140 times; then alculated
the "Max-Min" starting from Read 1 to 140 to generate the final
signal for % Effect calculation; The data was analyzed using Prism,
curve fitting equation "log(agonist) vs. response--Variable slope."
Table 2 shows the results of these assays.
TABLE-US-00002 TABLE 2 Cell Assay (FLIPR Calcium) Kappa # Compounds
EC.sub.50 (nM) 1 U-69593 46.93 2 5a 2.64 3 5b 9.7 4 7a 6.86 5 7b
3.76
[0156] As can be seen in Table 2, compound 5a provided improved
cell assays over U-69596 as well as compounds 5b, 7a, and 7b. The
response curve for compound 5a is shown in FIG. 1.
* * * * *